Skip to content

VNUS vs ClariVein for varicose veins

Randomised clinical trial comparing VNUS ClosureFAST with ClariVein for varicose veins

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN06552809
Enrollment
170
Registered
2012-08-16
Start date
2013-01-22
Completion date
Unknown
Last updated
2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Varicose veins, venous disease Circulatory System Varicose veins of other sites

Interventions

Treatment arm one is: VNUS ClosureFast radiofrequency ablation of the incompetent long or short saphenous vein with phlebectomies as per standard published treatment technique. Treatment arm two is:

Sponsors

Imperial College London (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adults over 18 years of age 2. Symptomatic long or short saphenous vein reflux < 0.5 seconds on colour duplex

Exclusion criteria

Exclusion criteria: 1. Current DVT 2. Recurrent varicose veins 3. Arterial disease (ABPI <0.8) 4. Veins less than 3 mm in diameter 5. Hypercoagulability 6. Patients who are unwilling to participate 7. Inability or unwillingness to complete questionnaires

Design outcomes

Primary

MeasureTime frame
1. A comparison of pain during the procedure measured using a patient-reported visual analogue score (VAS) comparing RFA and ClariVein® 2. Treatments will be performed under local anaesthetic with concomitant phlebectomy to treat varicosities 3. Pain during the procedure will be measured using a validated patient-reported Visual Analogue Score (VAS)

Secondary

MeasureTime frame
1. Quality of life at 30 days and 6 months measured using the Aberdeen Varicose Vein Severity Score (AVVSS) 2. Occlusion rates at 30 day and 6 months 3. Clinical success, including residual varicosities, complications and recurrence rates at 6 months 4. Improvements in generic quality of life using the EQ-5D at 30 days and 6 months 5. Clinical improvements measured using the Venous Clinical Severity Score (VCSS) at 30 days and 6 months 6. Time to return to work and normal activities assessed using a 30-day patient diary 7. A comparison of the cost-effectiveness of the treatment regimes will be made

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026